TY - JOUR
T1 - COVID-19 in people with rheumatic diseases
T2 - risks, outcomes, treatment considerations
AU - Grainger, Rebecca
AU - Kim, Alfred H.J.
AU - Conway, Richard
AU - Yazdany, Jinoos
AU - Robinson, Philip C.
N1 - Funding Information:
R.G. reports receiving speakers bureau honoraria from AbbVie, Cornerstones and Janssen, consulting fees from AstraZeneca and Novartis, and non-financial support from Janssen and Pfizer. A.H.J.K. reports receiving research grant funding from GlaxoSmithKline, consulting fees from Alexion Pharmaceuticals, Aurinia Pharmaceuticals, Exagen Diagnostics and GlaxoSmithKline, and speakers bureau honoraria from Aurinia Pharmaceuticals, Exagen Diagnostics and GlaxoSmithKline. R.C. reports receiving speakers bureau honoraria from AbbVie, Janssen, Roche and Sanofi. J.Y. reports receiving research grant funding from AstraZeneca and Gilead and consulting fees from AstraZeneca, Aurinia, Eli Lilly and Pfizer. P.C.R. reports receiving personal fees from AbbVie, Atom Biosciences, Eli Lilly, Gilead, Janssen, Novartis, Pfizer, Roche and UCB, meeting-attendance support from Bristol Myers Squibb, Pfizer and UCB, and grant funding from Janssen, Novartis, Pfizer and UCB.
Publisher Copyright:
© 2022, Crown.
PY - 2022/4
Y1 - 2022/4
N2 - The COVID-19 pandemic has brought challenges for people with rheumatic disease in addition to those faced by the general population, including concerns about higher risks of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and poor outcomes of COVID-19. The data that are now available suggest that rheumatic disease is associated with a small additional risk of SARS-CoV-2 infection, and that outcomes of COVID-19 are primarily influenced by comorbidities and particular disease states or treatments. Despite considerable advances in our knowledge of which therapeutic agents provide benefits in COVID-19, and of what constitutes effective vaccination strategies, the specific considerations that apply to people with rheumatic disease are yet to be definitively addressed. An overview of the most important COVID-19 studies to date that relate to people with rheumatic disease can contribute to our understanding of the clinical-care requirements of this population.
AB - The COVID-19 pandemic has brought challenges for people with rheumatic disease in addition to those faced by the general population, including concerns about higher risks of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and poor outcomes of COVID-19. The data that are now available suggest that rheumatic disease is associated with a small additional risk of SARS-CoV-2 infection, and that outcomes of COVID-19 are primarily influenced by comorbidities and particular disease states or treatments. Despite considerable advances in our knowledge of which therapeutic agents provide benefits in COVID-19, and of what constitutes effective vaccination strategies, the specific considerations that apply to people with rheumatic disease are yet to be definitively addressed. An overview of the most important COVID-19 studies to date that relate to people with rheumatic disease can contribute to our understanding of the clinical-care requirements of this population.
UR - http://www.scopus.com/inward/record.url?scp=85125271562&partnerID=8YFLogxK
U2 - 10.1038/s41584-022-00755-x
DO - 10.1038/s41584-022-00755-x
M3 - Review article
C2 - 35217850
AN - SCOPUS:85125271562
SN - 1759-4790
VL - 18
SP - 191
EP - 204
JO - Nature Reviews Rheumatology
JF - Nature Reviews Rheumatology
IS - 4
ER -